肝性脳症を伴う非代償性肝硬変患者に対する特殊アミノ酸経腸栄養剤の臨床的研究 -Historical Data の比較検討-

概要

論文の詳細を見る
A long-term clinical study of SF-1008C was perfermed in 96 patients with decompensated liver cirrhosis by periodic evaluation of nutritional status, symptomatic improvement and life prolongation. Definite improvement was seen in the second week of treatment in flapping tremor scores, number connection test times and encephalopathy severity. At 6 weeks, one-half of the patients were discharged, and at 3 months, more than 70% of all the patients improved to outpatient status. The Karnofsky performance scale also showed significant improvement after 2 weeks. In addition, Fischer's ratio (BCAA/AAA) and nutritional indexes showed improvement. Assessment of global improvement, safety and clinical usefulness revealed significant improvement with long-term use of SF-1008C.<BR>The cumulative survival rate in the SF-1008C treated group was significantly greater than that in the historical data group. Therefore, SF-1008C was considered to have high clinical value inprolonging the life of patients with decompensated liver cirrhosis.
社団法人日本肝臓学会の論文